Every article, report, and earnings note where ABVX appears.
Abivax S.A. (ABVX) jumps after a sharp post-data selloff, with traders stepping in on heavy volume. The rebound follows volatile Phase 3 ulcerative colitis results for obefazimod, where strong efficacy was overshadowed by safety concerns that sparked a steep earlier decline.
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Abivax’s lead asset obefazimod delivered strong Phase 3 maintenance data in ulcerative colitis, shifting the story toward regulatory execution. The balance sheet is solid enough to fund the next catalysts, but the stock remains highly dependent on one program.
Abivax S.A. (ABVX) climbs after reporting positive Phase 3 maintenance data for obefazimod in ulcerative colitis. The update strengthens the company’s case for a year-end NDA filing and shifts attention toward regulatory progress, while investors weigh volatility, dilution concerns, and the drug’s commercial potential.
Abivax S.A. (ABVX) plunges after-hours after a Phase 3 ulcerative colitis update showed strong efficacy but raised safety concerns. Investors are focusing on reported malignancy cases in the higher-dose arm, which are overshadowing the trial’s remission results and prompting a sharp re-rating of the stock.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ABVX ReportCancel anytime